191092-08-7 Usage
Description
(R)-3-(Tosyloxymethyl)-N-Boc-piperidine, with the molecular formula C17H27NO5S, is a piperidine derivative that serves as a crucial building block in the organic synthesis of pharmaceuticals and agrochemicals. (R)-3-(Tosyloxymethyl)-N-Boc-piperidine features a tosyl-protected Boc-piperidine structure, where the nitrogen of the piperidine is masked with a Boc group, and the hydroxyl group is protected with a tosyl group. This unique structure renders the compound a versatile intermediate for creating a range of biologically active compounds and is also recognized for its role in the preparation of chiral ligands and catalysts for asymmetric synthesis.
Uses
Used in Pharmaceutical Synthesis:
(R)-3-(Tosyloxymethyl)-N-Boc-piperidine is used as a key intermediate in the synthesis of various pharmaceuticals, due to its ability to be incorporated into a wide array of biologically active compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, (R)-3-(Tosyloxymethyl)-N-Boc-piperidine is utilized as a building block for the creation of compounds with pesticidal, herbicidal, or fungicidal properties, contributing to the development of more effective and targeted agrochemicals.
Used in Chiral Ligand and Catalyst Preparation:
(R)-3-(Tosyloxymethyl)-N-Boc-piperidine is also employed as a component in the preparation of chiral ligands and catalysts, which are essential for asymmetric synthesis. These chiral catalysts and ligands play a critical role in the production of enantiomerically pure compounds, which are often necessary for the desired biological activity of pharmaceuticals.
Organic Synthesis:
Within the broader field of organic synthesis, (R)-3-(Tosyloxymethyl)-N-Boc-piperidine is used as a versatile intermediate for the preparation of a variety of complex organic molecules, showcasing its utility in chemical research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 191092-08-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,0,9 and 2 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 191092-08:
(8*1)+(7*9)+(6*1)+(5*0)+(4*9)+(3*2)+(2*0)+(1*8)=127
127 % 10 = 7
So 191092-08-7 is a valid CAS Registry Number.
191092-08-7Relevant articles and documents
BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY
-
Paragraph 00837; 00838, (2021/04/23)
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF
-
, (2015/10/06)
The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.
FARNESYL PROTEIN TRANSFERASE INHIBITORS
-
Page/Page column 34, (2010/02/11)
Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.
